Mabylon discovers and develops therapeutic human antibodies to treatneurological disorders and severe allergies. Proprietary technology allows screening large numbers of sera and rapidly discovering target-specifc human antibodies.
Access to large populations and to knowledge of donor’s clinical history allows information on activity in human of the selected antibodies, as well as on most favorable target epitopes for effective and safe therapeutic antibodies.

Location

Wagistrasse 14, 8952 Schlieren

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2014
  • Number of employees in Switzerland
    10-19
Key business